Shareholding disclosure

Omega Fund IV LP

Declared position

2.96%

Threshold

Crossed upwards

Timeline

Published

02.02.2013

Transaction

30.01.2013

Voting rights breakdown

Voting rights acquired2.96%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAD2100015

Beneficial owner

Omega Fund IV LP

Declared address

Omega Fund IV L.P., Boston, MA 02116

sale on the market

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Omega Fund IV LP

Newron Pharmaceuticals S.p.A.02.02.2013TAD2100015

Disclosure summary

Omega Fund IV LP disclosed a holding in Newron Pharmaceuticals S.p.A. on the acquisition side, published by SIX Exchange Regulation on 02.02.2013, at 2.96% of voting rights. Notice category: Single shareholder.

Disclosed position

2.96%

Voting rights acquired

Voting rights acquired2.96%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Omega Fund IV LP disclosed a holding in Newron Pharmaceuticals S.p.A., published on 02.02.2013.

Publication date02.02.2013

Transaction date30.01.2013

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerOmega Fund IV LP

Declared addressOmega Fund IV L.P., Boston, MA 02116

CategorySingle shareholder

Voting rights acquired2.96%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAD2100015

Conditions

sale on the market

Source: SIX Exchange Regulation · Publication date: 02.02.2013

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open